Center for Cancer Nanotechnology Excellence for Translational Diagnostics (CCNE-TD)

转化诊断癌症纳米技术卓越中心 (CCNE-TD)

• 批准号: 9324940
• 负责人: SANJIV S GAMBHIR
• 金额: $ 204.91万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-04 至 2020-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9324940
• 关键词: Advanced Malignant Neoplasm; Aftercare; Animal Model; Biological Markers; Biopsy; Blood; Blood Tests; Blood specimen; CCNE1 gene; Cancer Center; Cancer Detection; Cancer Patient; Cells; Clinical; Clinical Management; Clinical Trials; Collaborations; Communities; Deoxyglucose; Development; Devices; Diagnostic; Discrimination; Disease; Early Diagnosis; Early treatment; Ensure; Five-Year Plans; Foundations; Funding; Future; Goals; Health Transition; Image; Image Guided Biopsy; Imaging technology; In Vitro; Individual; Indolent; Institutes; Intervention; Link; Location; Lung Neoplasms; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Massachusetts; Measures; Medical; Methods; Molecular Biology Techniques; Monitor; Nanotechnology; Neoplasm Circulating Cells; Oncologist; Patient-Focused Outcomes; Patients; Phase; Physicians; Positron-Emission Tomography; Process; Prostate; Recording of previous events; Regimen; Research; Research Proposals; Resources; Role; Running; Sampling; Sampling Studies; Scientist; Screening for cancer; Serinus; Signal Transduction; Site; Survival Rate; Technology; Testing; Therapeutic; Therapeutic Intervention; Tracer; Translating; Tumor Burden; Ultrasonography; Universities; Vesicle; Vision; anticancer research; base; biophysical analysis; cancer biomarkers; cancer diagnosis; cancer survival; cancer therapy; chemotherapy; clinical translation; cohesion; cost; cost effective; extracellular; extracellular vesicles; high risk; improved; in vivo; industry partner; innovation; lung cancer screening; lung visualization; molecular imaging; multidisciplinary; nano; nanoimaging; nanoparticle; nanoscience; nanosensors; next generation; novel; photoacoustic imaging; prognostic; programs; protein biomarkers; public health relevance; responders and non-responders; response; single cell analysis; single cell technology; surveillance study; synergism; translational diagnostics; tumor; tumor heterogeneity; tumorigenesis

 DESCRIPTION (provided by applicant): This Center for Cancer Nanotechnology Excellence for Translational Diagnostics (CCNE-TD) brings together scientists and physicians from Stanford University and the Massachusetts Institute of Technology to tackle the grand challenges of cancer early detection, image guided biopsy, monitoring response to therapy and early discrimination of aggressive vs. indolent disease. This research proposal is centered on our vision that in vitro diagnostics used in conjunction with in vivo molecular imaging can markedly impact future cancer patient management. Furthermore, we believe that nanotechnology can significantly advance both in vitro diagnostics through nanosensors, and in vivo diagnostics through nanoparticles for molecular imaging. The two major cancers that we will study are lung and prostate cancer. For lung cancer we will apply our technologies for early detection and to monitor response to therapy. For prostate cancer we will use our technologies to improve image guided biopsy, distinguish early aggressive vs. indolent cancers, and monitor response to therapy. We have assembled a highly interdisciplinary team of scientists with highly synergistic expertise and a long collaboration history. We will utilize significant resources at several small companies we have started and plan to further commercialize our most promising technologies. Project 1 focuses on the development of novel cancer triggered self-assembling and disassembling nanoparticles for positron emission tomography (PET) visualization of lung tumors and their response to chemotherapy. Project 2 focuses on the use of magneto- nanotechnology for blood biomarkers, single cell analysis of circulating tumor cells after enrichment and comprehensive analyses of blood-borne lung cancer markers. Project 3 focuses on the biophysical analysis of extracellular vesicles and their role in prostate cancer oncogenesis. Project 4 focuses on molecular imaging of prostate cancer with targeted nanobubbles for combined photoacoustic/ultrasound imaging and self-assembling nanoparticles for photoacoustic imaging. The Administrative Core will facilitate progress towards our milestones, Core 1 will provide resources for nano characterization and fabrication, and Core 2 will facilitate clinical translation by linking our nanotechnologies to existing patient samples, ad ongoing/new clinical trials. Leveraged access to clinical samples and studies include several large clinical trials for lung cancer (MD Anderson Lung Cancer Early Detection Moonshots Program), prostate cancer (The Prostate Active Surveillance Study (PASS) run by the Canary Foundation), and the Stanford-Google[X]- Duke baseline study to study the transition from health to illness in 10,000 individuals being launched in 2015. With our highly interactive and cohesive program focused on developing and validating nanotechnology for earlier cancer detection and prognostication, improved image guided biopsies, anti- cancer therapy response, we will imagine, invent, innovate, and translate.

 描述（由申请人提供）：该癌症纳米技术转化诊断卓越中心 (CCNE-TD) 汇集了来自斯坦福大学和麻省理工学院的科学家和医生，以应对癌症早期检测、图像引导活检、监测治疗反应以及早期区分侵袭性与惰性疾病的巨大挑战。这项研究提案的核心是我们的愿景，即体外诊断与体内分子成像结合使用可以显着影响未来的癌症患者管理。此外，我们相信纳米技术可以显着推进通过纳米传感器的体外诊断和通过分子成像纳米颗粒的体内诊断。我们将研究的两种主要癌症是肺癌和前列腺癌。对于肺癌，我们将应用我们的技术进行早期检测并监测治疗反应。对于前列腺癌，我们将利用我们的技术来改进图像引导活检、区分早期侵袭性癌症和惰性癌症，并监测治疗反应。我们组建了一支高度跨学科的科学家团队，拥有高度协同的专业知识和悠久的合作历史。我们将利用我们已经创办的几家小公司的大量资源，并计划进一步将我们最有前途的技术商业化。项目 1 重点开发新型癌症引发的自组装和拆卸纳米颗粒，用于肺肿瘤的正电子发射断层扫描 (PET) 可视化及其对化疗的反应。项目2的重点是利用磁纳米技术进行血液生物标志物、富集后循环肿瘤细胞的单细胞分析以及血源性肺癌标志物的综合分析。项目 3 重点关注细胞外囊泡的生物物理分析及其在前列腺癌肿瘤发生中的作用。项目 4 重点研究前列腺癌的分子成像，利用用于组合光声/超声成像的靶向纳米气泡和用于光声成像的自组装纳米颗粒。管理核心将促进我们实现里程碑的进展，核心 1 将提供纳米表征和制造的资源，核心 2 将通过将我们的纳米技术与现有患者样本、正在进行的/新的临床试验联系起来，促进临床转化。临床样本和研究的利用包括多项针对肺癌（MD 安德森肺癌早期检测登月计划）、前列腺癌（由金丝雀基金会开展的前列腺主动监测研究 (PASS)）的大型临床试验，以及 2015 年启动的斯坦福-谷歌[X]-杜克基线研究，旨在研究 10,000 名个体从健康到疾病的转变。 并验证纳米技术用于早期癌症检测和预测、改进图像引导活检、抗癌治疗反应，我们将想象、发明、创新和转化。